TGF-betas stimulate PAI-1 secretion of endometrial and endometriotic cells via Smad2/3 and ERK1/2

K Kloeppels, Cong Sui, Dorina R. Zoltan, H.-R. Tinneberg, Lutz Konrad
In: Geburtshilfe und Frauenheilkunde · 2011 · vol. 71(05) · doi:10.1055/s-0031-1280498 · W2316454294
article OA: closed CC0
Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-17 ⓘ

Transforming growth factor betas stimulate PAI-1 secretion in endometrial and endometriotic cells through Smad2/3 and ERK1/2 signaling pathways.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-06 · read from full text ⓘ

This study investigated the mechanism by which transforming growth factor betas (TGF-betas) stimulate plasminogen activator inhibitor-1 (PAI-1) secretion in endometrial and endometriotic cell lines. The researchers found that while both cell types increased PAI-1 production upon TGF-beta treatment, this upregulation was primarily mediated through Smad2/3 signaling with a secondary contribution from ERK1/2 pathways. Notably, endometriotic cells secreted significantly higher amounts of PAI-1 than normal endometrial cells, although serum levels in patients did not differ significantly from controls. This paper is centrally about endometriosis — specifically examining the molecular pathways driving PAI-1 overexpression in endometriotic lesions.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Objectives: In clinical trials, transforming growth factor betas (TGF-betas) and plasminogen activator inhibitor-1 (PAI-1) were observed to be highly expressed at endometriotic sites as well as in the peritoneal fluid or serum of patients who suffer from endometriosis. PAI-1 is one of the most important genes to test for upregulation of mRNA expression after treatment of cells with TGF-betas. Furthermore, PAI-1 might contribute to activation of latent TGF-betas via plasmin or is misregulated in cancer tissue, e.g. breast cancer. Thus, we have analyzed PAI-1 secretion in endometrial and endometriotic cells after treatment with TGF-betas and have measured PAI-1 serum levels in patients suffering from endometriosis.
Full text 2,728 characters · extracted from oa-doi-fallback · 5 sections · click to expand

Objectives

In clinical trials, transforming growth factor betas (TGF-betas) and plasminogen activator inhibitor-1 (PAI-1) were observed to be highly expressed at endometriotic sites as well as in the peritoneal fluid or serum of patients who suffer from endometriosis. PAI-1 is one of the most important genes to test for upregulation of mRNA expression after treatment of cells with TGF-betas. Furthermore, PAI-1 might contribute to activation of latent TGF-betas via plasmin or is misregulated in cancer tissue, e.g. breast cancer. Thus, we have analyzed PAI-1 secretion in endometrial and endometriotic cells after treatment with TGF-betas and have measured PAI-1 serum levels in patients suffering from endometriosis.

Methods

and Materials: Inhibitors for Smad2/3, p38/MAPK and ERK1/2 were used, which target Smad- and non-Smad-dependent pathways after stimulations with TGF-betas. Immortalized endometrial and endometriotic cells representative for stroma and epithelium were used for TGF-beta treatments in various combinations with the inhibitors. After three days collected supernatants were measured with PAI-1 ELISAs and cell numbers were determined.

Results

Secretion of PAI-1 was found only in stromal endometrial cells but not in epithelial cells. In contrast, endometriotic stromal and epithelial cells secreted higher amounts of PAI-1 compared with endometrial cells. In all cell lines secretion of PAI-1 was strongly upregulated by treatment with TGF-betas (TGF-beta1 to TGF-beta3). However, this increase was completely blocked by the Smad2/3 inhibitors in all cell lines. In general, the ERK1/2 inhibitor was less effective but also showed significant inhibiting effects on PAI-1 levels. In serum of endometriosis patients (n=35) we found no significantly different values compared to patients without endometriosis (n=34). Of note, in the secretory phase, values were lower compared with the proliferative phase or menstruation.

Conclusions

In our study, endometriotic cells secreted more PAI-1 than normal endometrial cells, which indicates a possible role of PAI-1 in the pathogenesis of endometriosis. Furthermore, PAI-1 secretion was stimulated by TGF-betas in both endometrial and endometriotic cells mainly via Smad2/3 and to a lesser extent via ERK1/2. Although PAI-1 serum levels were not higher in patients suffering from endometriosis, we are currently investigating tissue levels. We suggest that TGF-betas by upregulating secretion of PAI-1 might contribute to the pathogenesis of endometriosis.

Keywords

TGF-betas, PAI-1, Smad2/3, ERK, endometriosis

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-10-07T06:26:57.292555+00:00
License: CC0 · commercial use OK